Immunomic Therapeutics (ITI) is a clinical stage biotechnology company that is developing next generation vaccines based on the patented Lysosomal Associated Membrane Protein, or LAMP, Technology. The vaccine platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/17/13 | $3,000,000 |
Mid Atlantic Bio Angels | undisclosed | |
| 05/01/20 | $61,300,000 |
HLB Co. | undisclosed |
